[{"address1": "10955 Vista Sorrento Parkway", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 751 4493", "website": "https://www.januxrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.", "fullTimeEmployees": 103, "companyOfficers": [{"maxAge": 1, "name": "Dr. David Alan Campbell Ph.D.", "age": 64, "title": "President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 1130500, "exercisedValue": 0, "unexercisedValue": 107640504}, {"maxAge": 1, "name": "Mr. Byron  Robinson J.D., Ph.D.", "age": 59, "title": "Chief Strategy Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 727500, "exercisedValue": 0, "unexercisedValue": 7877545}, {"maxAge": 1, "name": "Mr. Matt  Whitmire", "title": "Vice President of Finance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maria  Dobek", "age": 35, "title": "Principal Accounting Officer & VP of Accounting", "yearBorn": 1989, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles M. Winter", "age": 55, "title": "Chief Technical Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 590400, "exercisedValue": 0, "unexercisedValue": 460878}, {"maxAge": 1, "name": "Mr. James  Pennington", "title": "General Counsel & Corporate Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Janeen  Doyle", "title": "Chief Corporate & Business Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andy Hollman Meyer", "age": 40, "title": "Chief Business Officer", "yearBorn": 1984, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zachariah  McIver D.O., Ph.D.", "age": 54, "title": "Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 24.0, "open": 24.04, "dayLow": 23.89, "dayHigh": 25.22, "regularMarketPreviousClose": 24.0, "regularMarketOpen": 24.04, "regularMarketDayLow": 23.89, "regularMarketDayHigh": 25.22, "payoutRatio": 0.0, "beta": 2.852, "forwardPE": -15.187499, "volume": 690650, "regularMarketVolume": 690650, "averageVolume": 833870, "averageVolume10days": 871210, "averageDailyVolume10Day": 871210, "bid": 23.86, "ask": 24.8, "bidSize": 9, "askSize": 9, "marketCap": 1460281728, "fiftyTwoWeekLow": 21.971, "fiftyTwoWeekHigh": 71.71, "priceToSalesTrailing12Months": 3326.382, "fiftyDayAverage": 24.5755, "twoHundredDayAverage": 35.15865, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 486461536, "profitMargins": 0.0, "floatShares": 44967087, "sharesOutstanding": 60093900, "sharesShort": 8733357, "sharesShortPriorMonth": 10261166, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.14729999, "heldPercentInsiders": 0.0659, "heldPercentInstitutions": 1.099, "shortRatio": 10.83, "shortPercentOfFloat": 0.21290001, "impliedSharesOutstanding": 60093900, "bookValue": 16.704, "priceToBook": 1.4547412, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -105641000, "trailingEps": -1.81, "forwardEps": -1.6, "enterpriseToRevenue": 1108.113, "enterpriseToEbitda": -3.407, "52WeekChange": -0.4761802, "SandP52WeekChange": 0.1513431, "quoteType": "EQUITY", "currentPrice": 24.3, "targetHighPrice": 200.0, "targetLowPrice": 25.0, "targetMeanPrice": 82.46154, "targetMedianPrice": 76.0, "recommendationMean": 1.21429, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 13, "totalCash": 996011008, "totalCashPerShare": 16.574, "ebitda": -142796992, "totalDebt": 22190000, "quickRatio": 46.854, "currentRatio": 47.035, "totalRevenue": 439000, "debtToEquity": 2.24, "revenuePerShare": 0.007, "returnOnAssets": -0.10507, "returnOnEquity": -0.12819, "grossProfits": -67949000, "freeCashflow": -30383376, "operatingCashflow": -59793000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -330.0205, "financialCurrency": "USD", "symbol": "JANX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchange": "NGM", "messageBoardId": "finmb_676965261", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "regularMarketChangePercent": 1.25, "regularMarketPrice": 24.3, "postMarketTime": 1755897908, "regularMarketTime": 1755892800, "corporateActions": [], "shortName": "Janux Therapeutics, Inc.", "longName": "Janux Therapeutics, Inc.", "postMarketChangePercent": 0.0, "postMarketPrice": 24.3, "postMarketChange": 0.0, "regularMarketChange": 0.299999, "regularMarketDayRange": "23.89 - 25.22", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 833870, "fiftyTwoWeekLowChange": 2.3289986, "fiftyTwoWeekLowChangePercent": 0.1060033, "fiftyTwoWeekRange": "21.971 - 71.71", "fiftyTwoWeekHighChange": -47.41, "fiftyTwoWeekHighChangePercent": -0.66113514, "fiftyTwoWeekChangePercent": -47.61802, "earningsTimestampStart": 1762459200, "earningsTimestampEnd": 1762459200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.81, "epsForward": -1.6, "epsCurrentYear": -2.21351, "priceEpsCurrentYear": -10.978039, "fiftyDayAverageChange": -0.27550125, "fiftyDayAverageChangePercent": -0.0112104025, "twoHundredDayAverageChange": -10.85865, "twoHundredDayAverageChangePercent": -0.3088472, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-11", "averageAnalystRating": "1.2 - Strong Buy", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1623418200000, "cryptoTradeable": false, "marketState": "CLOSED", "market": "us_market", "esgPopulated": false, "displayName": "Janux Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-08-23"}]